[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;[(2S,3S,4R,5R)-4-hydroxy-2,5-bis(hydroxymethyl)-2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-3-yl] hydrogen sulfate

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 喜树碱
• 英文名称: [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;[(2S,3S,4R,5R)-4-hydroxy-2,5-bis(hydroxymethyl)-2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-3-yl] hydrogen sulfate
• 化学式: C45H60N4O20S
• 分子量: 1009.0
• InChiKey: SQOIAFXIZHJUPK-UVYDIPIJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.48
• 重原子数：
  70
• 可旋转键数：
  12
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  354
• 氢给体数：
  9
• 氢受体数：
  22

文献信息

• COMBINATIONS OF LIPOSOMAL IRINOTECAN, 5-FU AND LEUCOVORIN FOR THE TREATMENT OF PANCREATIC CANCER
  申请人：Ipsen Biopharm Ltd.

  公开号：EP3266456A1

  公开（公告）日：2018-01-10

  Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.

  本文提供了通过单独使用或与其他治疗剂联合使用脂质体伊立替康（MM-398）治疗患者胰腺癌的方法。在一个实施方案中，脂质体伊立替康（MM-398）与 5-氟尿嘧啶和亮菌甲素联合给药。
• Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer
  申请人：Board of Regents, The University of Texas System

  公开号：US10894044B2

  公开（公告）日：2021-01-19

  The present disclosure relates to compositions and methods for treating cancer, more specifically to methods and compositions comprising a Topoisomerase I inhibitor and an α-PD-L1 antibody.

  本公开涉及治疗癌症的组合物和方法，更具体地说，涉及包含拓扑异构酶 I 抑制剂和 α-PD-L1 抗体的方法和组合物。
• Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
  申请人：Ipsen Biopharm Ltd.

  公开号：US10980795B2

  公开（公告）日：2021-04-20

  Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.

  本文提供了通过单独使用或与其他治疗剂联合使用脂质体伊立替康（MM-398）治疗患者胰腺癌的方法。在一个实施方案中，脂质体伊立替康（MM-398）与 5-氟尿嘧啶和亮菌甲素联合给药。
• Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)
  申请人：Ipsen Biopharm Ltd.

  公开号：US11071726B2

  公开（公告）日：2021-07-27

  Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of gastric cancer, including treatment of patients diagnosed with previously untreated gastric cancer. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.

  包括脂质体伊立替康、奥沙利铂和5-氟尿嘧啶在内的联合治疗方案可用于治疗胃癌，包括治疗确诊为以前未治疗过的胃癌患者。联合疗法可包括每两周一次服用脂质体伊立替康、奥沙利铂、亮菌素和 5-氟尿嘧啶。
• Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
  申请人：Ipsen Biopharm Ltd.

  公开号：US11344552B2

  公开（公告）日：2022-05-31

  Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.

  包括脂质体伊立替康、奥沙利铂和5-氟尿嘧啶在内的联合治疗方案可用于治疗胰腺癌，包括治疗确诊为先前未经治疗的转移性胰腺腺癌的患者。联合疗法可包括每两周一次服用脂质体伊立替康、奥沙利铂、亮菌素和 5-氟尿嘧啶。